Friend or foe? The elusive role of hepatic stellate cells in liver cancer
Liver fibrosis is a substantial risk factor for the development and progression of liver cancer,
which includes hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma …
which includes hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma …
Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
S Wang, SL Friedman - Science translational medicine, 2023 - science.org
Metabolic dysfunction–associated steatohepatitis (MASH) is a severe form of liver disease
that poses a global health threat because of its potential to progress to advanced fibrosis …
that poses a global health threat because of its potential to progress to advanced fibrosis …
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
XD Zhou, G Targher, CD Byrne, V Somers… - Hepatology …, 2023 - Springer
Background Fatty liver disease in the absence of excessive alcohol consumption is an
increasingly common condition with a global prevalence of~ 25–30% and is also associated …
increasingly common condition with a global prevalence of~ 25–30% and is also associated …
[HTML][HTML] Invited review liver fibrosis in NAFLD/NASH: From pathophysiology towards diagnostic and therapeutic strategies
Liver fibrosis, as an excess deposition of extracellular matrix (ECM) components, results
from chronic liver injury as well as persistent activation of inflammatory response and of …
from chronic liver injury as well as persistent activation of inflammatory response and of …
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
Nonalcoholic steatohepatitis (NASH) might soon become the leading cause of end-stage
liver disease and indication for liver transplantation worldwide. Fibrosis severity is the only …
liver disease and indication for liver transplantation worldwide. Fibrosis severity is the only …
[HTML][HTML] Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH
L Tao, X Yang, C Ge, P Zhang, W He, X Xu, X Li… - Cell Metabolism, 2024 - cell.com
The complex etiological factors associated with metabolic dysfunction-associated fatty liver
disease (MAFLD), including perturbed iron homeostasis, and the unclear nature by which …
disease (MAFLD), including perturbed iron homeostasis, and the unclear nature by which …
Expert panel recommendations: practical clinical applications for initiating and monitoring Resmetirom in patients with MASH/NASH and moderate to noncirrhotic …
M Noureddin, MR Charlton, SA Harrison… - Clinical …, 2024 - Elsevier
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects one in four people
in the United States and western Europe, with an important proportion developing metabolic …
in the United States and western Europe, with an important proportion developing metabolic …
[HTML][HTML] A global action agenda for turning the tide on fatty liver disease
Conclusions: This consensus-driven multidisciplinary fatty liver disease action agenda
developed by care providers, clinical researchers, and public health and policy experts …
developed by care providers, clinical researchers, and public health and policy experts …
NASH drug treatment development: challenges and lessons
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver
disease worldwide. Although NAFLD is tightly linked to obesity and type 2 diabetes, this liver …
disease worldwide. Although NAFLD is tightly linked to obesity and type 2 diabetes, this liver …
Steatotic liver disease
Steatotic liver disease is the overarching term for conditions characterised by abnormal lipid
accumulation in the liver (liver or hepatic steatosis). Steatotic liver disease encompasses …
accumulation in the liver (liver or hepatic steatosis). Steatotic liver disease encompasses …